Generic Name and Formulations:
Immobilized lipase (iLipase); per cartridge.
Alcresta Therapeutics, Inc.
Indications for RELiZORB:
To hydrolyze fats in enteral formula in patients ≥5yrs.
Adults and Children:
<5yrs: not established. ≥5yrs: use with enteral pump flow rates 24–120mL/hr. Use 1 cartridge for up to 500mL of enteral formula; if formula volume >500mL, may install a second cartridge for use immediately; max 2 cartridges per 24hr period. If formula volume <500mL per feeding, discard cartridge after use. For compatible enteral formulas, pumps, feed sets, and pump extension sets: see full labeling.
For use with enteral feeding only. Do not connect to any IV line, set up, or system. Do not reuse. Not for use with gravity feed systems. Monitor patients with fibrosing colonopathy; may progress to stricture formation. Exocrine pancreatic insufficiency: not studied.
Avoid enteral formulas containing insoluble fiber. Do not administer or add other medications through the cartridge or to the enteral feed line (in between the pump and cartridge). Concomitant porcine pancreatic enzyme replacement therapy: not studied.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC